
@ShahidNShah
EarliTec Dx raises $19.5M for products for children with Autism Spectrum Disorder (ASD) and early childhood vulnerabilities,
This round of financing will be used to support filing with the U.S. Food and Drug Administration (FDA) for 510K clearance, as well as commercialization of the company’s first product, the EarliPoint® Evaluation for ASD, which received breakthrough status in April 2021.
With technology developed by leading researchers at Children’s Healthcare of Atlanta, Emory University School of Medicine and Yale University, the company has completed clinical trials with more than 1,500 children—receiving breakthrough status for the EarliPoint® system in April of last year.
Continue reading at hitconsultant.net
It’s no secret that research studies and clinical trial sites struggle with recruitment. In recent years, the pharma industry has supported a more ‘patient-centered’ approach to clinical trial …
Posted Feb 21, 2022 Hybrid Clinical Trial
Connecting innovation decision makers to authoritative information, institutions, people and insights.
Medigy accurately delivers healthcare and technology information, news and insight from around the world.
Medigy surfaces the world's best crowdsourced health tech offerings with social interactions and peer reviews.
© 2025 Netspective Foundation, Inc. All Rights Reserved.
Built on Mar 28, 2025 at 1:45pm